Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholera Vaccines | 19 | 2019 | 19 | 5.350 |
Why?
|
| Typhoid Fever | 17 | 2019 | 19 | 5.070 |
Why?
|
| Cholera | 21 | 2019 | 21 | 4.780 |
Why?
|
| Diarrhea | 19 | 2019 | 56 | 4.240 |
Why?
|
| Escherichia coli Infections | 14 | 2019 | 37 | 3.660 |
Why?
|
| Escherichia coli Vaccines | 8 | 2019 | 10 | 2.800 |
Why?
|
| Dysentery, Bacillary | 8 | 2019 | 12 | 2.400 |
Why?
|
| Enterotoxigenic Escherichia coli | 8 | 2019 | 15 | 2.130 |
Why?
|
| Shigella Vaccines | 5 | 2019 | 5 | 2.050 |
Why?
|
| Child, Preschool | 45 | 2019 | 1095 | 2.020 |
Why?
|
| Vaccination | 10 | 2016 | 100 | 1.930 |
Why?
|
| Infant | 41 | 2019 | 895 | 1.930 |
Why?
|
| Child | 45 | 2019 | 2007 | 1.890 |
Why?
|
| Hepatitis E | 4 | 2018 | 6 | 1.840 |
Why?
|
| Salmonella Infections | 9 | 2018 | 11 | 1.810 |
Why?
|
| Developing Countries | 8 | 2019 | 38 | 1.680 |
Why?
|
| Adolescent | 42 | 2019 | 3127 | 1.610 |
Why?
|
| Disease Outbreaks | 7 | 2018 | 35 | 1.600 |
Why?
|
| Antibodies, Bacterial | 6 | 2019 | 31 | 1.470 |
Why?
|
| Mass Vaccination | 5 | 2016 | 7 | 1.430 |
Why?
|
| Influenza, Human | 7 | 2014 | 120 | 1.310 |
Why?
|
| Humans | 88 | 2019 | 28451 | 1.290 |
Why?
|
| Models, Theoretical | 3 | 2018 | 133 | 1.190 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 5 | 2019 | 6 | 1.190 |
Why?
|
| Shigella | 5 | 2019 | 7 | 1.110 |
Why?
|
| Immunity, Herd | 4 | 2019 | 5 | 1.110 |
Why?
|
| Fever | 7 | 2018 | 55 | 1.050 |
Why?
|
| Young Adult | 28 | 2019 | 2372 | 1.020 |
Why?
|
| India | 13 | 2018 | 62 | 1.000 |
Why?
|
| Administration, Oral | 14 | 2019 | 174 | 0.990 |
Why?
|
| Population Surveillance | 8 | 2014 | 122 | 0.930 |
Why?
|
| Bacterial Vaccines | 2 | 2012 | 7 | 0.900 |
Why?
|
| Paratyphoid Fever | 2 | 2019 | 3 | 0.870 |
Why?
|
| Female | 49 | 2019 | 18228 | 0.870 |
Why?
|
| Salmonella | 3 | 2018 | 3 | 0.850 |
Why?
|
| Vibrio cholerae | 3 | 2015 | 3 | 0.850 |
Why?
|
| Adult | 34 | 2019 | 8519 | 0.840 |
Why?
|
| Escherichia coli | 5 | 2014 | 79 | 0.790 |
Why?
|
| Viral Vaccines | 2 | 2011 | 13 | 0.790 |
Why?
|
| Salmonella typhi | 9 | 2018 | 10 | 0.790 |
Why?
|
| Male | 46 | 2019 | 17995 | 0.770 |
Why?
|
| Incidence | 12 | 2018 | 1072 | 0.760 |
Why?
|
| Vaccines, Conjugate | 4 | 2019 | 14 | 0.720 |
Why?
|
| Sanitation | 1 | 2018 | 5 | 0.720 |
Why?
|
| Hygiene | 1 | 2018 | 17 | 0.710 |
Why?
|
| Rotavirus Infections | 4 | 2019 | 10 | 0.710 |
Why?
|
| Mortality | 2 | 2019 | 108 | 0.660 |
Why?
|
| Enteritis | 2 | 2019 | 5 | 0.630 |
Why?
|
| Encephalitis, Japanese | 3 | 2015 | 3 | 0.620 |
Why?
|
| Immunization, Secondary | 2 | 2016 | 9 | 0.610 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 883 | 0.610 |
Why?
|
| Rural Population | 8 | 2016 | 290 | 0.590 |
Why?
|
| Vaccines, Inactivated | 9 | 2018 | 36 | 0.580 |
Why?
|
| Environmental Monitoring | 2 | 2013 | 30 | 0.580 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2012 | 8 | 0.570 |
Why?
|
| Water Supply | 1 | 2014 | 12 | 0.550 |
Why?
|
| Enteropathogenic Escherichia coli | 1 | 2014 | 3 | 0.550 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 48 | 0.550 |
Why?
|
| Diarrhea, Infantile | 1 | 2014 | 6 | 0.550 |
Why?
|
| Intestinal Perforation | 1 | 2014 | 9 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 8 | 2016 | 277 | 0.510 |
Why?
|
| Salmonella enterica | 4 | 2016 | 5 | 0.500 |
Why?
|
| Cause of Death | 1 | 2014 | 222 | 0.490 |
Why?
|
| Length of Stay | 1 | 2014 | 290 | 0.470 |
Why?
|
| Egypt | 12 | 2014 | 16 | 0.470 |
Why?
|
| Neisseria meningitidis, Serogroup A | 1 | 2012 | 1 | 0.460 |
Why?
|
| Residence Characteristics | 2 | 2016 | 161 | 0.450 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 312 | 0.450 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 30 | 0.440 |
Why?
|
| Africa South of the Sahara | 8 | 2018 | 12 | 0.440 |
Why?
|
| Infant, Newborn | 14 | 2019 | 560 | 0.420 |
Why?
|
| Feces | 6 | 2019 | 28 | 0.410 |
Why?
|
| Cambodia | 8 | 2014 | 8 | 0.400 |
Why?
|
| Bacteremia | 3 | 2016 | 50 | 0.400 |
Why?
|
| Double-Blind Method | 7 | 2018 | 519 | 0.400 |
Why?
|
| Bacterial Infections | 2 | 2012 | 40 | 0.400 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2018 | 158 | 0.390 |
Why?
|
| Campylobacter Infections | 2 | 2008 | 6 | 0.380 |
Why?
|
| Measles | 1 | 2009 | 2 | 0.380 |
Why?
|
| Immunization | 2 | 2019 | 27 | 0.380 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2008 | 7 | 0.370 |
Why?
|
| Tanzania | 9 | 2015 | 10 | 0.360 |
Why?
|
| Congresses as Topic | 2 | 2019 | 41 | 0.360 |
Why?
|
| Malaria | 4 | 2016 | 9 | 0.330 |
Why?
|
| Urban Population | 3 | 2017 | 77 | 0.330 |
Why?
|
| Ciprofloxacin | 3 | 2016 | 12 | 0.320 |
Why?
|
| Cost of Illness | 3 | 2018 | 60 | 0.320 |
Why?
|
| Prevalence | 6 | 2016 | 901 | 0.310 |
Why?
|
| Family Characteristics | 2 | 2017 | 35 | 0.300 |
Why?
|
| Middle Aged | 12 | 2018 | 11102 | 0.300 |
Why?
|
| Risk Factors | 5 | 2018 | 3527 | 0.280 |
Why?
|
| Cohort Studies | 8 | 2019 | 1662 | 0.280 |
Why?
|
| Databases, Factual | 2 | 2016 | 328 | 0.270 |
Why?
|
| Japanese Encephalitis Vaccines | 2 | 2015 | 2 | 0.270 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 52 | 0.270 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 401 | 0.260 |
Why?
|
| Bangladesh | 6 | 2019 | 7 | 0.250 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2016 | 35 | 0.250 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2016 | 14 | 0.250 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2016 | 155 | 0.240 |
Why?
|
| Immunization Schedule | 3 | 2019 | 21 | 0.220 |
Why?
|
| Nepal | 3 | 2014 | 9 | 0.220 |
Why?
|
| Escherichia coli Proteins | 3 | 2005 | 26 | 0.200 |
Why?
|
| Case-Control Studies | 5 | 2015 | 917 | 0.200 |
Why?
|
| Rotavirus Vaccines | 1 | 2019 | 6 | 0.190 |
Why?
|
| Antigens, Bacterial | 1 | 2019 | 18 | 0.190 |
Why?
|
| Geographic Information Systems | 1 | 2019 | 15 | 0.190 |
Why?
|
| Cross-Sectional Studies | 5 | 2016 | 1325 | 0.190 |
Why?
|
| Sensitivity and Specificity | 5 | 2012 | 523 | 0.190 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 30 | 0.190 |
Why?
|
| Growth Disorders | 1 | 2019 | 3 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 144 | 0.180 |
Why?
|
| Pregnant Women | 1 | 2018 | 5 | 0.180 |
Why?
|
| Hepatitis Antibodies | 1 | 2018 | 1 | 0.180 |
Why?
|
| Jaundice | 1 | 2018 | 4 | 0.180 |
Why?
|
| Treatment Outcome | 7 | 2015 | 3025 | 0.170 |
Why?
|
| Macaca mulatta | 1 | 2019 | 322 | 0.170 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 42 | 0.170 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1021 | 0.170 |
Why?
|
| Seroepidemiologic Studies | 2 | 2014 | 8 | 0.170 |
Why?
|
| Africa | 2 | 2014 | 24 | 0.170 |
Why?
|
| Pregnancy | 3 | 2017 | 743 | 0.170 |
Why?
|
| Hepatitis E virus | 2 | 2014 | 3 | 0.160 |
Why?
|
| Vietnam | 2 | 2014 | 4 | 0.160 |
Why?
|
| Drug Resistance, Multiple | 1 | 2017 | 7 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2014 | 25 | 0.160 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2016 | 49 | 0.160 |
Why?
|
| Washington | 1 | 2016 | 3 | 0.160 |
Why?
|
| Milk, Human | 1 | 2017 | 16 | 0.160 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2017 | 31 | 0.160 |
Why?
|
| Geography | 2 | 2014 | 32 | 0.160 |
Why?
|
| Education | 1 | 2016 | 33 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 3691 | 0.160 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 2 | 2014 | 3 | 0.160 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2017 | 49 | 0.160 |
Why?
|
| Endemic Diseases | 1 | 2016 | 4 | 0.150 |
Why?
|
| World Health Organization | 2 | 2014 | 15 | 0.150 |
Why?
|
| Indonesia | 1 | 2016 | 1 | 0.150 |
Why?
|
| Nigeria | 1 | 2016 | 1 | 0.150 |
Why?
|
| Uganda | 1 | 2016 | 5 | 0.150 |
Why?
|
| Enterotoxins | 3 | 2005 | 6 | 0.150 |
Why?
|
| Bacterial Toxins | 3 | 2005 | 17 | 0.150 |
Why?
|
| Immunity, Mucosal | 1 | 2016 | 5 | 0.150 |
Why?
|
| Poliovirus | 1 | 2016 | 3 | 0.150 |
Why?
|
| Antibody-Producing Cells | 1 | 2016 | 3 | 0.150 |
Why?
|
| Database Management Systems | 1 | 2016 | 11 | 0.150 |
Why?
|
| Public Health | 2 | 2014 | 68 | 0.150 |
Why?
|
| Hospitalization | 2 | 2016 | 395 | 0.150 |
Why?
|
| Immunoglobulin A | 4 | 2019 | 8 | 0.150 |
Why?
|
| Salmonella paratyphi A | 2 | 2013 | 2 | 0.150 |
Why?
|
| Aged | 6 | 2016 | 9561 | 0.140 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 69 | 0.140 |
Why?
|
| Research Design | 2 | 2015 | 277 | 0.140 |
Why?
|
| Haemophilus Vaccines | 1 | 2015 | 1 | 0.140 |
Why?
|
| Bacterial Capsules | 1 | 2015 | 4 | 0.140 |
Why?
|
| Haemophilus Infections | 1 | 2015 | 5 | 0.140 |
Why?
|
| Immunoglobulin G | 4 | 2019 | 103 | 0.140 |
Why?
|
| Mice | 2 | 2019 | 2372 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 722 | 0.140 |
Why?
|
| Health Expenditures | 1 | 2015 | 57 | 0.140 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 14 | 0.140 |
Why?
|
| Genotype | 2 | 2014 | 825 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 247 | 0.130 |
Why?
|
| Phenotype | 2 | 2014 | 662 | 0.130 |
Why?
|
| Bayes Theorem | 1 | 2014 | 64 | 0.130 |
Why?
|
| Salmonella Vaccines | 1 | 2013 | 1 | 0.130 |
Why?
|
| Internationality | 1 | 2013 | 20 | 0.130 |
Why?
|
| Animals | 5 | 2019 | 7456 | 0.130 |
Why?
|
| Population Density | 1 | 2013 | 6 | 0.130 |
Why?
|
| Educational Status | 1 | 2014 | 161 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 451 | 0.120 |
Why?
|
| Republic of Korea | 1 | 2012 | 8 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2013 | 158 | 0.120 |
Why?
|
| Computers, Handheld | 1 | 2012 | 7 | 0.120 |
Why?
|
| Niger | 1 | 2012 | 1 | 0.120 |
Why?
|
| Dengue | 1 | 2012 | 4 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 126 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2012 | 32 | 0.110 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2011 | 22 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 705 | 0.110 |
Why?
|
| Sex Factors | 1 | 2014 | 650 | 0.110 |
Why?
|
| Data Collection | 1 | 2012 | 167 | 0.110 |
Why?
|
| Vibrio cholerae O1 | 3 | 2015 | 3 | 0.110 |
Why?
|
| Rotavirus | 1 | 2010 | 3 | 0.100 |
Why?
|
| Orthomyxoviridae | 1 | 2010 | 14 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 221 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 326 | 0.100 |
Why?
|
| Fluoroquinolones | 1 | 2009 | 10 | 0.100 |
Why?
|
| Asia | 3 | 2013 | 16 | 0.090 |
Why?
|
| Gangliosides | 1 | 2008 | 6 | 0.090 |
Why?
|
| Indian Ocean Islands | 3 | 2013 | 3 | 0.090 |
Why?
|
| Cluster Analysis | 3 | 2013 | 123 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2017 | 1951 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2014 | 2921 | 0.080 |
Why?
|
| Azithromycin | 2 | 2004 | 13 | 0.080 |
Why?
|
| Hospitals | 3 | 2012 | 72 | 0.080 |
Why?
|
| Survival Rate | 1 | 2009 | 813 | 0.080 |
Why?
|
| Vaccines, Subunit | 2 | 2016 | 3 | 0.080 |
Why?
|
| Ghana | 2 | 2016 | 22 | 0.080 |
Why?
|
| Seasons | 1 | 2006 | 95 | 0.070 |
Why?
|
| Cryptosporidiosis | 1 | 2005 | 2 | 0.070 |
Why?
|
| Cryptosporidium parvum | 1 | 2005 | 2 | 0.070 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2005 | 1 | 0.070 |
Why?
|
| Tuberculoma, Intracranial | 1 | 2005 | 1 | 0.070 |
Why?
|
| Granuloma | 1 | 2005 | 13 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2005 | 51 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2005 | 30 | 0.070 |
Why?
|
| Placebos | 2 | 2015 | 66 | 0.070 |
Why?
|
| Biomedical Research | 2 | 2016 | 158 | 0.070 |
Why?
|
| Campylobacter coli | 1 | 2003 | 2 | 0.070 |
Why?
|
| Campylobacter jejuni | 1 | 2003 | 3 | 0.070 |
Why?
|
| Probability | 3 | 2012 | 148 | 0.060 |
Why?
|
| Cholera Toxin | 1 | 2002 | 5 | 0.060 |
Why?
|
| Age Factors | 2 | 2016 | 1123 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 717 | 0.060 |
Why?
|
| Serotyping | 2 | 2016 | 14 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 52 | 0.060 |
Why?
|
| Bacteria | 2 | 2012 | 44 | 0.060 |
Why?
|
| Prognosis | 3 | 2016 | 1374 | 0.050 |
Why?
|
| Shigella sonnei | 1 | 2019 | 1 | 0.050 |
Why?
|
| Vaccines, Attenuated | 1 | 2019 | 11 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2019 | 14 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 23 | 0.050 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 17 | 0.050 |
Why?
|
| Electrochemical Techniques | 1 | 2018 | 22 | 0.050 |
Why?
|
| Age Distribution | 2 | 2012 | 197 | 0.040 |
Why?
|
| Vaccines, Combined | 1 | 2017 | 4 | 0.040 |
Why?
|
| Lactation | 1 | 2017 | 14 | 0.040 |
Why?
|
| Guinea-Bissau | 1 | 2016 | 1 | 0.040 |
Why?
|
| Senegal | 1 | 2016 | 1 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2016 | 21 | 0.040 |
Why?
|
| Clinical Audit | 1 | 2016 | 1 | 0.040 |
Why?
|
| Poliomyelitis | 1 | 2016 | 2 | 0.040 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2016 | 3 | 0.040 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2016 | 2 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 17 | 0.040 |
Why?
|
| Weights and Measures | 1 | 2015 | 3 | 0.040 |
Why?
|
| Anthropometry | 1 | 2016 | 83 | 0.040 |
Why?
|
| Ethiopia | 1 | 2015 | 1 | 0.040 |
Why?
|
| Vibrio cholerae O139 | 1 | 2015 | 1 | 0.040 |
Why?
|
| Outpatients | 1 | 2015 | 54 | 0.040 |
Why?
|
| Democratic People's Republic of Korea | 1 | 2015 | 1 | 0.040 |
Why?
|
| Inpatients | 1 | 2015 | 52 | 0.040 |
Why?
|
| Fimbriae Proteins | 2 | 2005 | 5 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 472 | 0.030 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2014 | 3 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2014 | 24 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2014 | 47 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2014 | 66 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2013 | 32 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 874 | 0.030 |
Why?
|
| Poverty Areas | 1 | 2013 | 4 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2012 | 2 | 0.030 |
Why?
|
| Technology, Pharmaceutical | 1 | 2012 | 3 | 0.030 |
Why?
|
| Immunization Programs | 1 | 2012 | 16 | 0.030 |
Why?
|
| Communication | 1 | 2014 | 116 | 0.030 |
Why?
|
| Health Policy | 1 | 2012 | 72 | 0.030 |
Why?
|
| Hantavirus | 1 | 2012 | 1 | 0.030 |
Why?
|
| Orientia tsutsugamushi | 1 | 2012 | 1 | 0.030 |
Why?
|
| Rickettsia | 1 | 2012 | 3 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2012 | 21 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2014 | 462 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2012 | 25 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2012 | 26 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 298 | 0.030 |
Why?
|
| Decision Making | 1 | 2014 | 173 | 0.030 |
Why?
|
| Models, Biological | 1 | 2013 | 369 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2012 | 251 | 0.030 |
Why?
|
| Acute Disease | 1 | 2012 | 244 | 0.030 |
Why?
|
| Pharyngitis | 1 | 2010 | 12 | 0.030 |
Why?
|
| Cough | 1 | 2010 | 19 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2010 | 54 | 0.030 |
Why?
|
| Time Factors | 1 | 2015 | 2000 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2013 | 285 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 778 | 0.020 |
Why?
|
| Virulence Factors | 1 | 2005 | 7 | 0.020 |
Why?
|
| Brain | 1 | 2012 | 955 | 0.020 |
Why?
|
| Virulence | 1 | 2004 | 19 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 184 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2005 | 70 | 0.020 |
Why?
|
| Erythromycin | 1 | 2003 | 5 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 661 | 0.020 |
Why?
|
| Logistic Models | 1 | 2005 | 745 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2004 | 202 | 0.010 |
Why?
|
| Pediatrics | 1 | 2003 | 123 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2002 | 37 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 656 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 1299 | 0.010 |
Why?
|